Home › Therapeutic areas › Respiratory

Respiratory (27 companies · 9 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Respiratory Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 $608M 5
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 $536M 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 4 Phase 2 — 9
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 $2.20B 6
CNTB Connect Biopharma Respiratory 4 Phase 2 $37.3M 4
CTNM Contineum Therapeutics NeurologyRespiratory Rare 1 Phase 2 $375M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
IXHL Incannex Healthcare NeurologyRespiratory 1 Phase 2 $21.8M 2
INSM Insmed CardiovascularImmunology+3 Rare 7 Approved $26.7B 15
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 1 Phase 2 $10.4B 5
LQDA Liquidia CardiovascularImmunology+1 Rare 3 Approved $5.11B 9
MLYS Mineralys Therapeutics CardiovascularRenal+1 1 NDA Submitted $1.28B 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $47.7M 8
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.04B 6
PRME Prime Medicine GI/HepatologyRespiratory Rare 1 Phase 1 $699M 3
RNTX Rein Therapeutics Respiratory Rare 1 Phase 2 $30.7M 1
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 1 Phase 3 $4.7M 11
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 1 Approved $1.58B 11
SION Sionna Therapeutics Respiratory Rare 5 Phase 2 $139M 5
GPCR Structure Therapeutics MetabolicRespiratory Rare 1 Phase 3 $3.90B 5
UPB Upstream Bio Respiratory 2 Phase 2 $115M 3
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $560M 5
ZYME Zymeworks OncologyRespiratory 2 Approved $1.78B 12